

**UNITED STATES OF AMERICA
BEFORE THE
SECURITIES AND EXCHANGE COMMISSION**

August 21, 2026

In the Matter of Arbutus Biopharma
Corporation

ORDER GRANTING EXEMPTION FROM
EXCHANGE ACT RULE 13E-4(F)(3)

Arbutus Biopharma Corporation submitted a letter dated August 21, 2026, requesting that the Securities and Exchange Commission (“Commission”) grant an exemption from Exchange Act Rule 13e-4(f)(3) for the transaction described in its letter (“Request”).

Based on the representations and the facts presented in the Request, and subject to the terms and conditions described in the letter from the Division of Corporation Finance dated August 21, 2026, it is ORDERED that the request for an exemption from Exchange Act Rule 13e-4(f)(3) is hereby granted.

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority.

Tiffany Posil
Chief, Office of Mergers and Acquisitions
Division of Corporation Finance